367 related articles for article (PubMed ID: 33936100)
1. An Integrated Genomic, Proteomic, and Immunopeptidomic Approach to Discover Treatment-Induced Neoantigens.
Olsson N; Heberling ML; Zhang L; Jhunjhunwala S; Phung QT; Lin S; Anania VG; Lill JR; Elias JE
Front Immunol; 2021; 12():662443. PubMed ID: 33936100
[TBL] [Abstract][Full Text] [Related]
2. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.
Khodadoust MS; Olsson N; Wagar LE; Haabeth OA; Chen B; Swaminathan K; Rawson K; Liu CL; Steiner D; Lund P; Rao S; Zhang L; Marceau C; Stehr H; Newman AM; Czerwinski DK; Carlton VE; Moorhead M; Faham M; Kohrt HE; Carette J; Green MR; Davis MM; Levy R; Elias JE; Alizadeh AA
Nature; 2017 Mar; 543(7647):723-727. PubMed ID: 28329770
[TBL] [Abstract][Full Text] [Related]
3. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma.
Seliger B; Dunn T; Schwenzer A; Casper J; Huber C; Schmoll HJ
Scand J Immunol; 1997 Dec; 46(6):625-32. PubMed ID: 9420627
[TBL] [Abstract][Full Text] [Related]
5. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
Berg L; Rönnelid J; Sanjeevi CB; Lampa J; Klareskog L
Arthritis Res; 2000; 2(1):75-84. PubMed ID: 11219392
[TBL] [Abstract][Full Text] [Related]
7. LMP2+ proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes.
Sibille C; Gould KG; Willard-Gallo K; Thomson S; Rivett AJ; Powis S; Butcher GW; De Baetselier P
Curr Biol; 1995 Aug; 5(8):923-30. PubMed ID: 7583150
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface.
Hallermalm K; Seki K; Wei C; Castelli C; Rivoltini L; Kiessling R; Levitskaya J
Blood; 2001 Aug; 98(4):1108-15. PubMed ID: 11493458
[TBL] [Abstract][Full Text] [Related]
9. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
10. Proteogenomic discovery of cancer antigens: Neoantigens and beyond.
Kanaseki T; Tokita S; Torigoe T
Pathol Int; 2019 Sep; 69(9):511-518. PubMed ID: 31397525
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts.
Sundstrom JB; Ansari AA
Transpl Immunol; 1995 Dec; 3(4):273-89. PubMed ID: 8665146
[TBL] [Abstract][Full Text] [Related]
12. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
[TBL] [Abstract][Full Text] [Related]
13. IFNγ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation.
Goncalves G; Mullan KA; Duscharla D; Ayala R; Croft NP; Faridi P; Purcell AW
Front Immunol; 2021; 12():645770. PubMed ID: 33968037
[TBL] [Abstract][Full Text] [Related]
14. Proteolysis and class I major histocompatibility complex antigen presentation.
York IA; Goldberg AL; Mo XY; Rock KL
Immunol Rev; 1999 Dec; 172():49-66. PubMed ID: 10631936
[TBL] [Abstract][Full Text] [Related]
15. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
Zhang X; Qi Y; Zhang Q; Liu W
Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
[TBL] [Abstract][Full Text] [Related]
16. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
17. Schwann cells co-cultured with stimulated T cells and antigen express major histocompatibility complex (MHC) class II determinants without interferon-gamma pretreatment: synergistic effects of interferon-gamma and tumor necrosis factor on MHC class II induction.
Kingston AE; Bergsteinsdottir K; Jessen KR; Van der Meide PH; Colston MJ; Mirsky R
Eur J Immunol; 1989 Jan; 19(1):177-83. PubMed ID: 2493382
[TBL] [Abstract][Full Text] [Related]
18. Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme.
Yang I; Kremen TJ; Giovannone AJ; Paik E; Odesa SK; Prins RM; Liau LM
J Neurosurg; 2004 Feb; 100(2):310-9. PubMed ID: 15086239
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
[TBL] [Abstract][Full Text] [Related]
20. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
